Shots:

• The P-III study (FLAMES) evaluates senaparib (PARP inhibitor) as monotx. maintenance treatment in 393 patients with FIGO stage III/IV ovarian cancer. Senaparib was jointly developed by Junshi Biosciences & IMPACT Therapeutics
• The trial met its 1EPs & the study’s interim analysis results show that senaparib can extend the PFS in patients with advanced ovarian cancer regardless of the BRCA mutation status
• Junshi Biosciences and IMPACT Therapeutics will communicate with regulatory authorities regarding a new drug application for the drug shortly. The fixed-dose combination capsules of senaparib and temozolomide received ODD from the US FDA in Aug 2022 for adult patients with SCLC

Ref: Globe Newswire | Image: Junshi